-
Preclinical metabolism and the disposition of vornorexant/TS‐142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-03-16 Yoshihiro Konno, Shunsuke Kamigaso, Hidetoh Toki, Shuichi Terasaka, Hirohiko Hikichi, Hiromi Endo, Jun‐Ichi Yamaguchi, Akiko Mizuno‐Yasuhira
-
The role of histamine H1 receptor in the anterior cingulate cortex on nociception level following acute restraint stress in male rats Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-03-14 Roxana Daniali, Fatemeh Zeraati, Mozhdeh Mohammadi, Rasool Haddadi
-
Adherence to newer second‐line oral antidiabetic drugs among people with type 2 diabetes—A systematic review Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-03-07 Nynne Sophie Holdt‐Caspersen, Claus Dethlefsen, Peter Vestergaard, Ole Hejlesen, Stine Hangaard, Morten Hasselstrøm Jensen
-
The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-03-06 Joanna Parkinson, Jesper Sundell, Dinko Rekić, Karin Nelander, Hans Ericsson, Ahmad Ebrahimi, Corina Dota, Mikael Sunnåker
-
Identification and neuroprotective properties of NA‐184, a calpain‐2 inhibitor Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-03-02 Michel Baudry, Yubin Wang, Xiaoning Bi, Yun Lyna Luo, Zhijun Wang, Zeechan Kamal, Alexander Shirokov, Ed Sullivan, Dennis Lagasca, Hany Khalil, Gary Lee, Kathy Fosnaugh, Philippe Bey, Shujaath Medi, Greg Coulter
-
Phenotype versus genotype to optimize cancer dosing in the clinical setting—focus on 5‐fluorouracil and tyrosine kinase inhibitors Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-03-02 Jennifer H. Martin, Peter Galettis, Alex Flynn, Jennifer Schneider
-
Effects of vasoactive substances on biomechanics of small resistance arteries of male and female Dahl salt‐sensitive rats Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-02-29 Eric A. Mensah, Noriko Daneshtalab, Reza Tabrizchi
-
-
Progress in the treatment of diabetic cardiomyopathy, a systematic review Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-02-26 Yiyi Shou, Xingyu Li, Quan Fang, Aqiong Xie, Yinghong Zhang, Xinyan Fu, Mingwei Wang, Wenyan Gong, Xingwei Zhang, Dong Yang
Diabetic cardiomyopathy (DCM) is a condition characterized by myocardial dysfunction that occurs in individuals with diabetes, in the absence of coronary artery disease, valve disease, and other conventional cardiovascular risk factors such as hypertension and dyslipidemia. It is considered a significant and consequential complication of diabetes in the field of cardiovascular medicine. The primary
-
Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B‐cell malignancies: Results from the CITADEL‐101 study Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-02-26 Jia Li, Xiaohua Gong, Xing Liu, Xiang Liu, Ke Szeto, Xuejun Chen
-
Pharmacology education in the medical curriculum: Challenges and opportunities for improvement Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-02-15 Pius S. Fasinu, Teresa W. Wilborn
The knowledge and application of pharmacology is essential for safe prescribing and administration of drugs. In this narrative review, the challenges to pharmacology education in the medical curricula were broadly identified to include issues around content and pedagogies. The increasing number of approved drugs and drug targets, expanding field of pharmacology and the often-changing treatment guidelines
-
Role of G protein-coupled receptor kinases (GRKs) in β2-adrenoceptor-mediated glucose uptake Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-02-08 Seungmin Ham, Saori Mukaida, Masaaki Sato, Peter Keov, Tore Bengtsson, Sebastian Furness, Nicholas D. Holliday, Bronwyn A. Evans, Roger J. Summers, Dana S. Hutchinson
Truncation of the C-terminal tail of the β2-AR, transfection of βARKct or over-expression of a kinase-dead GRK mutant reduces isoprenaline-stimulated glucose uptake, indicating that GRK is important for this response. We explored whether phosphorylation of the β2-AR by GRK2 has a role in glucose uptake or if this response is related to the role of GRK2 as a scaffolding protein. CHO-GLUT4myc cells expressing
-
2-Deoxyglucose and hydroxychloroquine HPLC-MS–MS analytical methods and pharmacokinetic interactions after oral co-administration in male rats Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-31 Dongxiao Sun, Sangyub Kim, Deepkamal Karelia, Yibin Deng, Cheng Jiang, Junxuan Lü
-
Epigenetics in obesity: Mechanisms and advances in therapies based on natural products Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-31 Peng Chen, Yulai Wang, Fuchao Chen, Benhong Zhou
-
The impact of phosphodiesterase-5 inhibition or angiotensin-converting enzyme inhibition on right and left ventricular remodeling in heart failure due to chronic volume overload Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-29 Tereza Tykvartova, Matus Miklovic, Martin Kotrc, Petra Skaroupkova, Ludmila Kazdova, Jaroslava Trnovska, Vojtech Skop, Michal Kolar, Jiri Novotny, Vojtech Melenovsky
-
A systematic review on experimental studies about patient adherence to treatment Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-11 Frans Folkvord, Ana Roca-Umbert Würth, Karlijn van Houten, Aad R. Liefveld, Jim Ingebretsen Carlson, Nadine Bol, Emiel Krahmer, Gwenn Beets, Rachel Drbohlav Ollerton, Eva Turk, Harald Hrubos-Strøm, Hamza Nahoui, Gunnar Einvik, Henrik Schirmer, Anne Moen, Jaime Barrio-Cortes, Beatriz Merino-Barbancho, Peña Arroyo, Giuseppe Fico, Luís Midão, Rute Sampaio, João A. Fonseca, Katja Geipel, Kathrin Scheckenbach
-
Development of a pharmaceutical science systematic review process using a semi-automated machine learning tool: Intravenous drug compatibility in the neonatal intensive care setting Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-11 D. Thisuri N. De Silva, Brioni R. Moore, Tobias Strunk, Michael Petrovski, Vanessa Varis, Kevin Chai, Leo Ng, Kevin T. Batty
-
Real-world treatment outcomes of immune checkpoint inhibitors used off-label in oncology: A comprehensive cancer institution experience Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-09 Sandra Fontanals, Anna Esteve, Andrea González, Cristina Ibáñez, Ricard Mesía, Ana Clopés
-
Antioxidant potential of chlorogenic acid in Age-Related eye diseases Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-08 Yu Tang, Chi Fang, Jian Shi, Huimei Chen, Xiong Chen, Xiaolei Yao
Oxidative stress is an important mechanism of aging, and in turn, aging can also aggravate oxidative stress, which leads to a vicious cycle. In the process of the brain converting light into visual signals, the eye is stimulated by harmful blue-light radiation directly. Thus, the eye is especially vulnerable to oxidative stress and becomes one of the organs most seriously involved during the aging
-
Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-04 Cheng Jiang, Jiancheng Qian, Xin Jiang, Shuohan Zhang, Junxian Zheng, Hongwei Wang
-
The blockade of the TGF-β pathway alleviates abnormal glucose and lipid metabolism of lipodystrophy not obesity Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2024-01-04 Wen-Dong Xu, Shui-Zheng Lai, Jia Zhao, Shi-Jie Wei, Xue-Ying Fang, Yi-Yi Liu, Xiang-Lu Rong, Jiao Guo
-
Human organ chips for regenerative pharmacology Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-12-27 Girija Goyal, Chaitra Belgur, Donald E. Ingber
-
A descriptive pharmacokinetic/pharmacodynamic analysis of ceftazidime-avibactam in a case series of critically ill patients with augmented renal clearance Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-12-27 Ying Xu, Jian Tang, Binbin Yuan, Xuemei Luo, Pei Liang, Ning Liu, Danjiang Dong, Lu Jin, Weihong Ge, Qin Gu
To describe the pharmacokinetics/pharmacodynamics (PK/PD) of a 2 h infusion of ceftazidime-avibactam (CAZ-AVI) in critically ill patients with augmented renal clearance (ARC). A retrospective review of all critically ill patients with ARC who were treated with CAZ-AVI between August 2020 and May 2023 was conducted. Patients whose 12-h creatinine clearance prior to CAZ-AVI treatment and steady-state
-
Clinical considerations on monkeypox antiviral medications: An overview Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-12-27 Fariba Pourkarim, Taher Entezari-Maleki
-
Investigation of the cytotoxicity induced by cannabinoids on human ovarian carcinoma cells Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-12-15 Kartheek Sooda, Simon J. Allison, Farideh A. Javid
-
Co-created in vivo pharmacology practical classes using the novel organism Lumbriculus variegatus Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-12-08 Julanta J. Carriere, Nia A. Davies, Margaret R. Cunningham, Melisa J. Wallace, Aidan Seeley
-
Development and evaluation of an escape room based on general pharmacokinetics: Students' perceptions of its motivational climate Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-11-29 Anneke van Houwelingen, Freija ter Heegde, Wendy Boschloo, Leonie Piek, Theo Wubbels
-
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-11-29 Monica Patel, Natasha L. Grimsey, Samuel D. Banister, David B. Finlay, Michelle Glass
The rapid structural evolution and emergence of novel synthetic cannabinoid receptor agonists (SCRAs) in the recreational market remains a key public health concern. Despite representing one of the largest classes of new psychoactive substances, pharmacological data on new SCRAs is limited, particularly at the cannabinoid CB2 receptor (CB2). Hence, the current study aimed to characterize the molecular
-
A systematic review of knowledge, attitude and practice of pharmacogenomics in pediatric oncology patients Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-11-27 Claire Moore, Smaro Lazaraki, Tayla Stenta, Marliese Alexander, Rachel Phan Nguyen, David A. Elliott, Rachel Conyers
Pharmacogenomics remains underutilized in clinical practice, despite the existence of internationally recognized, evidence-based guidelines. This systematic review aims to understand enablers and barriers to pharmacogenomics implementation in pediatric oncology by assessing the knowledge, attitudes, and practice of healthcare professionals and consumers. Medline, Embase, Emcare, and PsycINFO database
-
Time to treat the climate and nature crisis as one indivisible global health emergency Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-11-23 Kamran Abbasi, Parveen Ali, Virginia Barbour, Thomas Benfield, Kirsten Bibbins-Domingo, Stephen Hancocks, Richard Horton, Laurie Laybourn-Langton, Robert Mash, Peush Sahni, Wadeia Mohammad Sharief, Paul Yonga, Chris Zielinski
Over 200 health journals, call on the United Nations, political leaders, and health professionals to recognize that climate change and biodiversity loss are one indivisible crisis and must be tackled together to preserve health and avoid catastrophe. This overall environmental crisis is now so severe as to be a global health emergency. The world is currently responding to the climate crisis and the
-
Quantitative analysis of the UDP-glucuronosyltransferase transcriptome in human tissues Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-11-20 Lucas Zhou, Abelardo D. Montalvo, Joseph M. Collins, Danxin Wang
-
Effects of the HIV-1 maturation inhibitor GSK3640254 on QT interval in healthy participants Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-11-14 Ying Zhang, Mark Bush, Parto Yazdani, Joyce Zhan, Bo Wen, Veronica Bainbridge, Brian R. Wynne, Samit Joshi, Max Lataillade
-
Genes ingenuity pathway analysis unveils smoothelin-like 1 (SMTNL1) as a key regulatory protein involved in sodium pentobarbital-induced growth inhibition in breast cancer Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-11-09 Bingwei Li, Xiaoyan Zhang, Xueting Liu, Ailing Li, Jianqun Han
-
Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-11-02 B. Miguel-Lillo, Sara Sánchez-Vidaurre, L. Pérez Díaz, A. Paravisini
-
Validity, sensitivity and specificity of a measure of medication adherence instrument among patients taking oral anticoagulants Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-27 Mariana Dolce Marques, Rafaela Batista dos Santos Pedrosa, Henrique Ceretta Oliveira, Maria Cecília Bueno Jayme Gallani, Roberta Cunha Matheus Rodrigues
Although self-report instruments are currently considered a valuable tool for measuring adherence, due to their low cost and ease of implementation, there are still important factors that impact measurement accuracy, such as social desirability and memory bias. Thus, the Global Assessment of Medication Adherence Instrument (GEMA) was developed to provide an accurate measure of this construct. The aim
-
The roles of CYP2C19 and CYP3A4 in the in vitro metabolism of β-eudesmol in human liver: Reaction phenotyping and enzyme kinetics Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-30 Nadda Muhamad, Kesara Na-Bangchang
-
The role of plasma concentrations and drug characteristics of beta-blockers in fall risk of older persons Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-26 K. J. Ploegmakers, E. P. van Poelgeest, L. J. Seppala, S. C. van Dijk, L. C. P. G. M. de Groot, S. Oliai Araghi, N. M. van Schoor, B. Stricker, K. M. A. Swart, A. G. Uitterlinden, R. A. A. Mathôt, N. van der Velde
-
Investigation of the human metabolism and disposition of the prolyl hydrolase inhibitor daprodustat using IV microtracer with Entero-Test bile string Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-26 Guoying Tai, Fangming Xia, Cathy Chen, Adrian Pereira, Jill Pirhalla, Xiusheng Miao, Graeme Young, Claire Beaumont, Liangfu Chen
-
Student perceptions of scientific writing in pharmacology: Student generation of collaborative rubrics to score a social pharmacology writing project Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-27 Terri Enslein, Edward Kosack, Hanna N. Wetzel
-
Experimental pharmacology in precision medicine Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-26 Alicja Urbaniak, Kenneth E. Thummel, Ayoade N. Alade, Allan E. Rettie, Bhagwat Prasad, Amedeo De Nicolò, Jennifer H. Martin, David N. Sheppard, Michael F. Jarvis
1 INTRODUCTION Following the initial sequencing of the human genome, it was widely predicted that this knowledge would lead to transformational advances in the identification, prevention, and treatment of disease.1 The terms “Precision Medicine” and “Personalized Medicine” have been used interchangeably over the last two decades to describe almost all applications of genomic information in the development
-
Effects of (−)-MBP, a novel 5-HT2C agonist and 5-HT2A/2B antagonist/inverse agonist on brain activity: A phMRI study on awake mice Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-13 Preeti K. Sathe, Gargi R. Ramdasi, Kaylie Giammatteo, Harvens Beauzile, Shuyue Wang, Heng Zhang, Praveen Kulkarni, Raymond G. Booth, Craig F. Ferris
-
Dose rationale for gabapentin and tramadol in pediatric patients with chronic pain Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-06 Paul Healy, Luka Verrest, Mariagrazia Felisi, Adriana Ceci, Oscar Della Pasqua
-
Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-06 Benjamin Berger, Priska Kaufmann, Matthias Berse, Alexander Treiber, Nathalie Grignaschi, Jasper Dingemanse
-
Biochemical and genetic biomarkers associated with nicotine dependence in Mexican smokers Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-10-03 Gissela Borrego-Soto, Yadira Xitlalli Perez-Paramo, Francisco Hernández-Cabrera, Fatima Miroslaba Alvarado-Monroy, Gilberto Borrego, Alejandro Robles-Zamora, Philip Lazarus, Augusto Rojas-Martinez
-
A phase I, single-center, open-label study to investigate the absorption, distribution, metabolism and excretion of encorafenib following a single oral dose of 100 mg [14C] encorafenib in healthy male subjects Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-09-29 Lance Wollenberg, Erik Hahn, Jason Williams, Kevin Litwiler
-
IPEx: A gamification tool for learner application of pharmacologic principles of opioid use, misuse, and addiction Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-09-27 Kelly Karpa, Josie Ward, Melanie Stegman, Arthur Berg, Shou Ling Leong
-
Autocrine positive feedback of tumor necrosis factor from activated microglia proposed to be of widespread relevance in chronic neurological disease Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-09-26 Ian A. Clark, Bryce Vissel
Over a decade's experience of post-stroke rehabilitation by administering the specific anti-TNF biological, etanercept, by the novel perispinal route, is consistent with a wide range of chronically diminished neurological function having been caused by persistent excessive cerebral levels of TNF. We propose that this TNF persistence, and cerebral disease chronicity, largely arises from a positive autocrine
-
A randomized, double-blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-09-23 Igor Makarenko, Artem Dorotenko, Sergey Noskov, Veniamin Banko, Valeria Saparova, Alexandr Khokhlov, Evgeniia Zoreeva, Andrey Nedorubov, Bella Zinnatulina, Maria Gefen, Roman Drai
The pharmacodynamic (PD) similarity between GP40141, a proposed romiplostim biosimilar, and reference romiplostim was evaluated. Pharmacokinetics and safety were also assessed.
-
Neuroprotective effect of Kurarinone against corticosterone-induced cytotoxicity on rat hippocampal neurons by targeting BACE1 to activate P13K–AKT signaling – A potential treatment in insomnia disorder Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-09-23 Guoqing Wu, Yanyan Wu
The hippocampus has been implicated in the pathogenesis of insomnia disorder (ID) and the purpose of this study was to investigate the neuroprotective mechanism of the natural flavone Kurarinone (Kur) on hippocampal neurotoxicity as a potential treatment of ID. The effect of Kur on hippocampal neuronal cell (HNC) viability and apoptosis were assessed by Cell counting kit-8 (CCK-8) assay and flow cytometry
-
Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC-H 106 Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-09-23 Heejin Lee, Hye-Ji Kim, Dong-Kyu Choi, Eu n.-A. Ko, Jae-Hyeog Choi, Yohan Seo, Sion Lee, Soong-Hyun Kim, Sejin Jung, Minwoo Kim, Dongwan Kang, Chun-Young Im, Gi-Hun Bae, Sung-Cherl Jung, Oh-Bin Kwon
The importance of vesicular monoamine transporter 2 (VMAT2) in dopamine regulation, which is considered crucial for neuropsychiatric disorders, is currently being studied. Moreover, the development of disease treatments using histone deacetylase (HDAC) inhibitors (HDACi) is actively progressing in various fields. Recently, research on the possibility of regulating neuropsychiatric disorders has been
-
Impact of amiodarone use on metoprolol concentrations, α-OH-metoprolol concentrations, metoprolol dosing and heart rate: A cross-sectional study Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-09-21 Sabrina Robert, Marc-Olivier Pilon, Essaïd Oussaïd, Maxime Meloche, Grégoire Leclair, Martin Jutras, Marie-Josée Gaulin, Ian Mongrain, David Busseuil, Jean-Claude Tardif, Marie-Pierre Dubé, Simon de Denus
Small studies suggest that amiodarone is a weak inhibitor of cytochrome P450 (CYP) 2D6. Inhibition of CYP2D6 leads to increases in concentrations of drugs metabolized by the enzyme, such as metoprolol. Considering that both metoprolol and amiodarone have β-adrenergic blocking properties and that the modest interaction between the two drugs would result in increased metoprolol concentrations, this could
-
Rapid changes of mRNA expressions of cardiac ion channels affected by Torsadogenic drugs influence susceptibility of rat hearts to arrhythmias induced by Beta-Adrenergic stimulation Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-09-15 Katarina Hadova, Jana Kmecova, Katarina Ochodnicka-Mackovicova, Eva Kralova, Gabriel Doka, Lenka Bies Pivackova, Peter Vavrinec, Tatiana Stankovicova, Peter Krenek, Jan Klimas
Drug-induced long QT syndrome (LQTS) and Torsades de Pointes (TdP) are serious concerns in drug development. Although rats are a useful scientific tool, their hearts, unlike larger species, usually do not respond to torsadogenic drugs. Consequently, their resistance to drug-induced arrhythmias is poorly understood. Here, we challenged rats with rapid delayed rectifier current (Ikr)-inhibiting antibiotic
-
Changes in plasma alpha-1 acid glycoprotein following hemorrhagic trauma: Possible role in dose differences of ALM drug therapy in rat and pig resuscitation Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-08-29 Hayley L. Letson, Jodie L. Morris, Geoffrey P. Dobson
The binding of drugs to plasma proteins is an important consideration in drug development. We have reported that the dose of adenosine, lidocaine, and magnesium (ALM) fluid therapy for resuscitation from hemorrhagic shock is nearly 3-times higher for pigs than rats. Since lidocaine strongly binds to serum alpha-1-acid glycoprotein (AGP), the aim of the study was to investigate the effect of hemorrhagic
-
Suspected oncologic adverse reactions associated with interleukin-23 inhibitors in EudraVigilance: Comparative study and gender distribution Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-08-24 Fabrizio Calapai, Carmen Mannucci, Luigi Cardia, Mariaconcetta Currò, Gioacchino Calapai, Emanuela Esposito, Ilaria Ammendolia
Psoriasis is a chronic inflammatory skin disease characterized by plaque formation. Interleukin (IL)-23 is upregulated in psoriatic lesions and is thought to be a major regulator of the Th17 pathway in psoriasis pathogenesis. Three monoclonal antibodies targeting the IL-23p19 subunit, guselkumab, tildrakizumab, and risankizumab, have been approved for psoriasis therapy. The balance between cytokines
-
Response to “Evaluating Adverse Events in Databases” Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-08-17 Fabrizio Calapai, Carmen Mannucci, Luigi Cardia, Mariaconcetta Currò, Gioacchino Calapai, Emanuela Esposito, Ilaria Ammendolia
Katie Lovell and Steven R. Feldman commented and criticized our recent manuscript entitled “Suspected oncologic adverse reactions associated with IL-23 inhibitors in EudraVigilance: comparative study and gender distribution.” In the commentary, they list some methods to be used to determine the causal relationship between a drug and an adverse reaction. First of all, they cite randomized placebo-controlled
-
Effects of pharmacological doses of niacin on subacute glucocorticoid-induced testicular damage in rats Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-08-17 E. Azimi Zangabad, Tahoora Shomali, L. Roshangar
Glucocorticoid excess adversely affects male reproduction. This study evaluates effects of pharmacological doses of niacin on testicular structure and function in dexamethasone-treated rats. Adult rats (48) were randomly assigned to 6 equal groups: (1) Negative control (NC): normal rats; (2) Positive control (PC): dexamethasone at 7 mg/kg/day by intraperitoneal injections for 7 days; groups 3–6 (N50
-
Evaluating adverse events in databases Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-08-17 Katie Lovell, Steven R. Feldman
In this issue, Calapai et al. reported a potential association between oncologic adverse reactions and interleukin-23 (IL-23)1 inhibitor use in psoriasis patients using the EudraVigilance database for spontaneous adverse event reports.2 The study evaluated suspected adverse events from 2020 to 2022 with a reported 53 events related to oncologic disease development following the use of IL-23 blockers:
-
Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-08-11 Robert Freeze, Kelly W. Yang, Timothy Haystead, Philip Hughes, Scott Scarneo
Rheumatoid arthritis (RA) is a complex autoimmune disease characterized by hyperactive immune cells within the joints, which leads to inflammation, bone degeneration, and chronic pain. For several decades, frontline immunomodulators such as the anti-tumor necrosis factor (TNF) biologics adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade) have successfully managed disease progression
-
Experimental training in molecular pharmacology education based on drug–target interactions Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-08-07 Luna Ge, Kai Cheng, Yuang Zhang, Junling Li, Wei Chen, Guanhua Song, Lin Wang
Drug development has been challenged by the dual drawbacks involving unpredictable disease outcomes and drug resistance, which has placed greater demands on pharmacology education. Molecular pharmacology, as a frontier crossover field of pharmacology, focuses on the research of new drugs and targets. However, due to the lack of a systematic experimental training system, molecular pharmacology has not
-
Could cannabinoids provide a new hope for ovarian cancer patients? Pharmacol. Res. Perspect. (IF 2.6) Pub Date : 2023-08-01 Rimanee Kaur, Farideh A. Javid
It is known that gynecological cancers remain a worldwide problem and as shown by the statistics, there is a need for new gynecological cancer treatments. Cannabinoids, the pharmacologically active compounds of the Cannabis sativa plant, have been used for many centuries by individuals as a symptomatic treatment to alleviate pain, nausea, vomiting, and to help stimulate appetite. Research has revealed